The retina is a thin, light-sensitive layer located at the back of the eye. It contains two main types of photoreceptors: rods, which enable vision in low light, and cones, which provide color and daylight vision. In dogs affected by pap-PRA, a genetic mutation interferes with the normal function and survival of these cells. Over time, the photoreceptors gradually deteriorate, leading to a slow but progressive decline in vision.
Clinical signs of pap-PRA typically develop later in life, although the exact age of onset may vary depending on breed and genetic background. One of the earliest signs is night blindness, where dogs struggle to see in dim light or darkness. Owners may notice hesitation when walking in low-light environments, reluctance to go outside at night, or increased bumping into objects. As the disease progresses, daytime vision becomes affected, leading to difficulty navigating familiar surroundings, reduced spatial awareness, and challenges recognizing obstacles.
Eventually, pap-PRA leads to complete blindness. Although this condition is irreversible, it is not painful, and most dogs adapt well by relying on their other senses such as smell and hearing. With consistent environment and supportive care, affected dogs can maintain a good quality of life even after vision loss.
The pap-PRA DNA Health Test is designed to detect the specific genetic mutation associated with this form of Progressive Retinal Atrophy. The test is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The collected DNA is analyzed in a specialized laboratory to determine whether the dog carries zero, one, or two copies of the mutation. Because DNA remains unchanged throughout life, testing can be performed at any age, including before clinical signs appear.
Results are generally reported in three categories:
- Clear (Normal): The dog does not carry the pap-PRA mutation and will not develop or pass on the condition.
- Carrier: The dog carries one copy of the mutation but is usually unaffected during its lifetime. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a high likelihood of developing Progressive Retinal Atrophy (pap-PRA) with progressive vision loss.
Genetic testing for pap-PRA is highly valuable for breeders, veterinarians, and dog owners. Breeders can use test results to make informed breeding decisions that reduce or eliminate the mutation from breeding populations while maintaining healthy genetic diversity. Avoiding carrier-to-carrier breeding significantly reduces the risk of producing affected puppies.
For dog owners, understanding a dog’s genetic status allows for early preparation and supportive care. Dogs identified as at risk can benefit from environmental adjustments such as maintaining consistent home layouts, using scent and sound cues, and providing safe, predictable navigation areas. Routine veterinary eye examinations can also help monitor progression. While there is currently no cure for pap-PRA, supportive management can greatly improve quality of life.
The Progressive Retinal Atrophy (pap-PRA) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine ocular health, and helps reduce the impact of this inherited retinal degeneration in future generations.
